Molnupiravir is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in non-hospitalized patients who are at high risk for progression to severe COVID-19 (eg, hospitalization, death) or in patients for
authorization for lagevrio™ (molnupiravir) capsules
The giant drugmaker is seeking the emergency authorization for molnupiravir, which it says cut hospitalizations and deaths by half among patients with early COVID-19 symptoms
Nirmatrelvir is an oval, pink tablet
pregistry
It is not known if LAGEVRIO will harm your baby if you take
It is important that you complete the full 5 days of treatment
3 Molnupiravir should be started as soon as possible after a diagnosis of symptomatic COVID-19 has been made and within five days of symptom onset
Do not stop taking molnupiravir without talking to your doctor
“Among 76 patients with viral rebound, 12 of 68 nonusers, 1 of 6 molnupiravir users, and neither of the nirmatrelvir-ritonavir users died of COVID-19,” the researchers advise